The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...

Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, according to a national survey conducted this year by Mercer, a human resources ...

U.S. drugmaker Eli Lilly said on Wednesday it will invest $4.5 billion to create a new center in Indiana that will focus on ...

The company is also preparing for the potential market introduction of orforglipron, an oral obesity drug, which is expected to further alleviate capacity constraints. The analyst pointed out that ...

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Amgen (AMGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Yee from ...

The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.

This expansion is seen as a strategic move to address the complex challenges of forecasting supply and backlog for its drug Zepbound in the short term. The company is also preparing for the potential ...